

# Microbiology Overview for IP&C

---

CHRISTINE TURENNE, PHD, FCCM, ABMM

DEC 2022

A solid green horizontal bar at the bottom of the slide.

# Overview

---

- Review of laboratory testing methods
- Antimicrobial testing, interpretation
- “Walk through the lab”
- Key IP&C bugs

# Clinical microbiology testing in Manitoba

---

## Shared Health – Diagnostic Services

- Health Sciences Center (HSC)
- St-Boniface Hospital (SBH)
- Westman Lab (WL in Brandon)
- Thompson; The Pas

## Cadham Provincial Laboratory (CPL)


## National Microbiology Laboratory (NML)

## Dynacare (Private)

## Who works in these labs?

- Medical microbiologists (MDs: Fellows of the Royal College), Clinical microbiologists (CCM or ABMM board certified PhDs); PhDs
- Medical Laboratory Technologists (CSMLS certified MLTs, ~ 2 yr program minimum); BSc or other college diploma
- Medical Laboratory Assistants (MLAs)
- Admin/Support staff

# Microbiological Testing in a nutshell



# Laboratory testing methods

---

# Microscopy: The Gram Stain

---

**Purpose:** phenotypic characterization of bacteria by brightfield microscopy; quickly provides a hint as to if/what organism may be causing infection


**Mechanism:** based on thickness of the peptidoglycan layer in the bacteria cell wall

**Steps:**

- Step 1: Crystal Violet (primary stain)
- Step 2: Iodine (mordant; forms complex with CV)
- Step 2: alcohol and/or acetone (rapid decolorization)
- Step 3: basic fuchsin or safranin (pink counter stain)


**Results:**

- **Gram-positive:** thick peptidoglycan layer (retains CV stain) = blue
- **Gram-negative:** thin (easily decolorized) = pink
- Shape and distribution (cocci, bacilli, clusters, chains, etc)
- Antibiotics can impact both staining and morphology



wikipedia


Gram-positive cocci in clumps  
(e.g. *Staphylococcus*)



Gram-positive cocci in chains  
(e.g. *Streptococcus*)



Gram-positive bacilli  
(e.g. *Bacillus*)




Gram-negative bacilli  
(e.g. *E. coli*)



Gram-negative diplococci  
(e.g. *Neisseria*)



Yeast-like organisms  
(e.g. *Candida*)



# Examples of other stains

---

## Fungal stains:

- **Calcofluor White** (fluorescent): non-specific, but binds to chitin and cellulose found in fungal cells; direct from specimen
- **Lactophenol aniline blue** (brightfield): to determine fungal morphology from culture

Acid-Fast Bacilli (**AFB stains**): contain dense, waxy cell wall that resist acid-alcohol decolorization

- **Auramine** (fluorescent): non-specific fluorescent stain, binds to mycolic acids of mycobacteria
- **Kinyoun** (brightfield): basic fuchsin as primary stain




Calcofluor white: e.g. "Large broad-based budding yeast-like organisms seen suggestive of *Blastomyces* species"




← Fluorescent microscopy →

Auramine: AFB (e.g. TB)



Lactophenol blue: moulds (e.g. *Aspergillus*)



← Brightfield microscopy →

Kinyoun: AFB (e.g. TB)



# Detection by culture or NAAT

---

Most organisms can be cultured, but it's not always simple

Bacteria: most require nutrients, humidity and heat. Some need special media or atmospheres. Almost all clinically relevant species grow within 24-72 hours.

Fungi: Require nutrients and humidity. Many moulds require 7 – 20 days to grow, but yeast (e.g. *Candida*, *Cryptococcus*) grows quickly on routine media (like bacteria).

Mycobacteria: Rapid-growers (e.g. *M. abscessus*) within 7 days; Slow-growers (e.g. TB) require 2 – 12 weeks to grow, some in special conditions.

Viruses and chlamydia: Diagnosis primarily molecular (e.g. Nucleic acid amplification test or NAAT).

Parasites: Diagnosis primarily is by microscopy, NAAT or serology directly from specimen.

# Types of culture media

---

**Nutritive** media: supports growth of most non-fastidious organisms

- E.g. Tryptic soy agar, Sabouraud's (fungi)

**Enriched** media: used to enhance growth of particular organisms

- E.g. blood agar (or BA)
- E.g. chocolate agar (contains lysed blood) for better growth of *H. influenzae* or *N. meningitidis*
- E.g. buffered charcoal-yeast extract (BCYE) for *Legionella*


**Selective** media: contains inhibitory agents to select for some bacteria, while inhibiting others

- E.g. phenylethyl alcohol (PEA) for selection of anaerobic Gram-positive organisms
- E.g. Thayer-Martin (also enriched) contains antibiotics for selection of *N. gonorrhoeae*

**Differential** media: contains factors that allow some bacteria to exhibit distinguishing characteristics from other bacteria

- E.g. MacConkey (also selective) which can differentiate lactose-fermenting (LF) Gram-negative bacteria from non-LF.

# Examples of Culture Plates




Gonococci on chocolate  
agar



*E. coli* on BA




Streptococci on BA:  
can observe hemolysis



*Aspergillus* on SAB

# Species identification

- Microscopy & colonial morphology
- Biochemical tests
- Automated systems
- Matrix-assisted laser desorption ionization–time of flight (MALDI-TOF)



MALDI-TOF



# Molecular Detection

---


- Detection of nucleic acids of pathogens has revolutionized the microbiology laboratory.
- Virtually any organism can be identified using molecular techniques.
- Advantage: very high sensitivity, high specificity, reduced turn around time and irrelevance to viability; can be multiplexed
- Disadvantage: cost, risk of contamination, problems with validation/applicability/relevance, space requirement, expertise. Agent-specific, cannot detect unknown pathogens.
- E.g. SARS-CoV2 PCR, Influenza, RSV, TB, Pertussis

# Antimicrobial testing


---

# Antimicrobial susceptibility testing (AST)

- Purpose: to predict the likely outcome of treatment with the antimicrobial agent tested, for a specific organism.
- Results are derived from established breakpoints, which are **minimal inhibitory concentration (MIC)** or **zone diameter values** used to categorize an organism as **S, I, R**
- CLSI\* Interpretive categories:
  - **Susceptible (S)**: infection due to the strain may be treated with dosage of agent recommended for that infection.
  - **Intermediate (I)**: isolates with MICs usually attainable in blood/tissue but response may be lower. Clinical applicability where drugs are concentrated or when high dose can be given. Also includes buffer zone for inherent variability in test methods.
  - **Resistant (R)**: strains not inhibited by usually achievable systemic concentrations using normal dosages and where clinical efficacy has not been reliable.



**MIC:** the lowest concentration of antibiotics that inhibits bacterial growth, i.e. 2 µg/mL







# AST methods using in the laboratory:

## MIC methods:

Broth microdilution panel




Gradient diffusion (e.g. Etest)



Automated AST (e.g. **VITEK 2™**)

## Disc diffusion a.k.a. Kirby-Bauer (KB):



(zone diameter measured in mm)

# Example of an AST profile

Specimen: Urine

Pathogen: E. coli >10<sup>8</sup> CFU/mL

 *Reported to the physician*

<b>Isolate 1</b>	<b>MIC</b>	<b>Interpretation</b>	<b>Breakpoint</b>
Ampicillin	>16	R	>16
Pip/Tazo	<16	S	>16
Amox/Clav	<8	S	>16
Cefazolin	<4	S	>16
Gentamicin	<2	S	>8
TMP/SMX	<2	S	>2
Nitrofurantoin	<32	S	>64
Ciprofloxacin	<1	S	>2

# Walk through the micro laboratory

---

# Microbiology Lab Benches

---

Specimen Processing

Blood Cultures

Urines

Fluids and Tissues (sterile)

Wounds (non-sterile)

Respiratory

Gastrointestinal/GI (stool)

Genitourinary/GU (genital)

Mycology

Mycobacteriology

Surveillance

- MRSA, CPE, VRE

Molecular

- NAAT, sequencing

QC

Teaching

- i.e. MLT students, clinical microbiology fellows, Infectious Diseases & Medical Microbiology residents

# Specimen collection

---

Technically, not a lab bench (pre-analytical) but considered by many:

## **THE MOST IMPORTANT PART!**

Poor specimen collection can lead to:

- **Specimen rejection** (e.g. improper/no label, improper/non-sterile container, leaking container, improper test request, etc.)
- **Poor results** (garbage in, garbage out), leading to misdiagnosis and inappropriate therapy (e.g. swabs, contaminated by normal flora, insufficient volume, prolonged transport, etc)

Consult the Shared Health Lab Information Manual (or CPL Guide to Services) for instructions on specimen collection

# Specimen processing

---

Specimen is received by the laboratory


Specimen is registered into the system

Specimen is set-up for the test requested

- Planting media (manually in a BSC or automated)
- Incubation at the right temperature and atmosphere

Appropriate culture media are selected, inoculated, and incubated under appropriate temperature and atmospheric conditions.

Direct stains are performed (microscopy)



<https://www.mountsinai.on.ca/>



# Blood Cultures

---

Blood culture set: aerobic and anaerobic (10 mL blood each) x 2 sites (= 4 bottles)

Blood culture bottles are incubated for 5 days in automated system.

Positive cultures:


- Gram stain – result called immediately (critical result)
- Appropriate media is inoculated to isolate the organism.
- MALDI-ToF is performed on a sweep from 4hrs of bacterial growth for faster reporting of species identification (if Gram shows a pure culture).

All organisms are reported; AST performed if not a potential contaminant.

Potential contaminants (if detected in only 1 of 2 sites):

- *Bacillus* (and other aerobic large Gram-positive bacilli), *Corynebacterium*, *Cutibacterium*, Coagulase-negative Staph, “viridans group” streptococci, *Micrococcus* spp., etc.

# Blood Cultures





# Urine

---

Specimen processed only if clinically justified (as indicated on the requisition)


Only typical uropathogens will be identified, e.g.

- *Enterobacterales*, *P. aeruginosa*, GBS, *S. aureus*, *S. saprophyticus*, enterococci
- Workup of atypical organisms requires lab consult
- Mixed/contaminated urine, non-pathogens (skin/vaginal flora) not identified

New chromogenic media reduces TAT

All urines will have a quantitative culture done

- Report will give pathogen and quantity per litre
  - Eg.  $>1 \times 10^8$ /L of *E. coli*



# Sterile fluids / Tissues

---

CSF, aseptically obtained tissues, biopsies, fluids, bone, aspirates, prosthetic devices

Gram stain – result reported ASAP

~ All organisms that grow on routine media are reported

If an unusual organism is anticipated or suspected, extra testing and/or precautions may be required and must be requested

- e.g. slow growing organism, AFB, fungus, anaerobes

~Most organisms will get AST if truly sterile specimen.

Extent of work-up may depend on likelihood of contamination

# Wound Cultures

---

Skin/subcutaneous tissue swabs, ulcer swabs, fluids/tissue from non-sterile sites, iv tips, bile

The lab will identify all routine pathogens, with AST if appropriate

- E.g. B-hemolytic streptococci, *S. aureus*, *P. aeruginosa*

Other organisms identified (+/- AST) if

- Pure culture
- Mixed but predominant

Anaerobic work-up only from sites where anaerobes are not normal flora (e.g. deep wounds)

# Respiratory Specimens - Bacterial

---

Lab screens specimen with gram stain to determine acceptability for culture (specimen quality is important) and to give rapid information.

Exceptions: no screening for CF or pediatric patients

Lab will culture for routine bacterial pathogens only, e.g.:

- *S. pneumoniae*
- *H. influenzae*
- *Enterobacteriales*, *Pseudomonas*, Gram-negative rods
- *S. aureus*
- GAS


Specific request and specimens needed for TB (or AFB), *Legionella*, *B. pertussis* (PCR), fungi, etc.

# Sputum Gram Stains

Culture = *S. pneumoniae*:



Acceptable  
for culture:  
few epi cells



Unacceptable for culture: mixed oral  
flora, high number of epithelial cells

Culture =  
*E. coli*:



# Respiratory Specimens - Viral

---

- 3 testing approaches:
  - Single target assay: SARS-CoV2 (COVID-19)
  - Quadplex assay: SARS-CoV2, Flu A, Flu B, RSV
  - Multiplex assay (CPL only): as above, plus rhinovirus, enterovirus, adenovirus, parainfluenza x4, endemic coronaviruses x3, human metapneumovirus, bocavirus
    - Requests are prioritized for ICU patients with ILI, outbreak investigations, transplant patients
- Which testing is performed depends on circulating viruses (seasonality, pandemicity), availability of testing (equipment and staffing), patient management needs, etc.
- **Hospital labs** focus on rapid testing for patient management needs and are limited to Influenza (A and B), RSV and SARS-CoV2.
- **CPL labs** have a slightly longer TAT but have higher throughput capacity and ability to test for an expanded panel of respiratory viruses under specific circumstances.

# Stool Culture

---

## Stool culture for Enteric pathogens

- Now done only at CPL by NAAT, followed by culture if positive
- Pathogens sought are: *E. coli* O157:H7, other Shiga-toxin producing strains, *Campylobacter*, *Shigella*, *Salmonella*
- Cultures for *Vibrio cholera*, *Aeromonas spp*, are on request only

## *C. difficile* testing (2 steps):

- **Unformed stool** from patient suspected of having *C. diff* disease
- Step 1 (screen): detection of *C. diff* antigen glutamate dehydrogenase (GD) by rapid antigen test. If positive, must do step 2.
- Step 2: Alethia<sup>®</sup> (DNA amplification assay) to detect **toxigenic** *C. diff*.



# Genital Specimens

---

Specimens for sexually transmitted infections or STI (GC and chlamydia) are generally by molecular assays (at CPL)

Culture of GC (cervical swab in female or urethral swabs in males) can be done; requires special media. Useful for AST.

“Vaginal cultures” are **not** typically done

- Exceptions: GBS in pregnancy, vaginitis/STD in children
- Gram stains provide diagnosis of vaginosis and candidiasis. Wet mounts or antigen for trichomonas



# Surveillance Specimens

---

Chromogenic media that includes antibiotics (selective) and other components for colony differentiation


MRSA *S. aureus* = pink



VRE *E. faecalis* = blue or  
*E. faecium* = pink



Carbapenemase-producing  
Enterobacterales (CPE)  
*Klebsiella* = blue or *E. coli* =  
pink



# Key IP&C Bugs

---

i.e. organisms reported to IP&C

# MRSA

Methicillin-Resistant *S. aureus*

Gram-positive cocci in clusters,  
catalase+, coagulase+,  
“methicillin” R, *mecA*+

Similar infection spectrum to  
MSSA

- MRSA: 1.5 – 2x increased risk of mortality (Cosgrove 2003)

Resistant to all  $\beta$ -lactams

Acquisition of altered PBP  
(PBP2a, encoded by *mecA*  
gene)

=== BLOOD CULTURE (Two bottles submitted) ===

Site RT. FA  
GRAM STAIN BLOOD  
Gram positive cocci - clusters.

CRITICAL RESULT PHONED/FAXED at 10:43 on 5 Nov 22 to [REDACTED] by L6HBF  
:Gram result notified, read back ok  
CRITICAL RESULT PHONED/FAXED at 13:20 on 6 Nov 22 to [REDACTED] by L6HBF  
:MRSA positive notified, read back ok.

CULTURE

1) Staphylococcus aureus  
A methicillin resistant S.aureus (MRSA) has been isolated. Follow the MRSA Infection control guidelines. Resistance or sensitivity to oxacillin is predictive of resistance or sensitivity to cefazolin and cloxacillin.

Oxacillin.....	(1)
Erythromycin .....	R
Clindamycin .....	R
Linezolid .....	S
Daptomycin .....	S
Vancomycin .....	S
Tetracycline .....	S
Trimethoprim-sulfamethoxazole	S
	(1)

S = Susceptible I = Intermediate R = Resistant

COMMENTS  
A copy of this report has been generated for Infection Control.

# VRE

## Vancomycin-resistant enterococci

Gram-positive cocci in chains, catalase-, PYR+, BE+

Vancomycin resistance: altered cell wall precursors prohibits vancomycin binding; **plasmid-mediated**, *vanA* or *vanB* genes, typically in *E. faecium* & *E. faecalis*

Mostly colonization, but can cause UTI, wound infections, sepsis

*E. faecalis* causes 90% of infections, but most VRE are *E. faecium*

*E. casseliflavus* & *E. gallinarum* (not VRE)

- vanC: low-level R to vanco; chromosomal

```
===== URINE CULTURE =====  
  
Site MSU  
  
CULTURE  
  
1) >1 x 10E8/L Enterococcus faecium  
A vancomycin-resistant Enterococcus (VRE) has been isolated.  
Nitrofurantoin is only indicated for the treatment of uncomplicated urinary tract infection.  
Resistance or sensitivity to ampicillin can be used to predict resistance or sensitivity to oral amoxicillin for the treatment of uncomplicated lower urinary tract infections.  
  
Ampicillin ..... (1)  
Ciprofloxacin ..... R  
Linezolid ..... S  
Vancomycin ..... R  
Tetracycline ..... R  
Nitrofurantoin ..... R  
Doxycycline ..... I  
..... (1)  
  
S = Susceptible I = Intermediate R = Resistant  
  
COMMENTS  
A copy of this report has been generated for Infection Control.
```

# CPE, CPO

Carbapenemase Producing Enterobacterales  
Carbapenemase Producing Organisms

\***Plasmid-mediated** carbapenemase: e.g.  
KPC, NDM, VIM, IMP, OXA-48-like

Serious threat, usually resistant to many  
(or all) first-line antibiotics

Occurs mostly in *Enterobacterales* (CPE),  
e.g. *E. coli*, *K. pneumoniae*, *E. cloacae*  
*cplx*

Can also occur in non-*Enterobacterales*  
(CPO) such as *P. aeruginosa* and  
*Acinetobacter* spp.

=== BLOOD CULTURE (Two bottles submitted) ===

Site LT PICC  
GRAM STAIN BLOOD  
Gram Negative bacilli

CRITICAL RESULT PHONED/FAXED at 10:13 on 22 Sep 22 to [REDACTED] by L6ADR  
:read back pos gram results  
CRITICAL RESULT PHONED/FAXED at 15:04 on 22 Sep 22 to [REDACTED] by L6ADR  
:read back 4 hr ID update  
CRITICAL RESULT PHONED/FAXED at 14:12 on 25 Sep 22 to [REDACTED] by L6NC  
:CARB positive, with read back

## CULTURE

1) *Klebsiella pneumoniae*  
This isolate is a carbapenemase-producing organism and demonstrates reduced susceptibility to carbapenems. Consultation with the Infectious Disease Service is recommended. Follow the Infection Prevention and Control guidelines for Antibiotic Resistant Organisms (ARO) and/or contact Infection Prevention and Control practitioner. Colistin has limited clinical efficacy. It should be used in combination with one or more active antimicrobial agents whenever possible.

	(1)	
Ampicillin .....	R	
Piperacillin-tazobactam .....	R	
Cefazolin .....	R	
Ceftriaxone.....	R	
Gentamicin .....	S	
Tobramycin .....	S	
Ciprofloxacin .....	S	
Trimethoprim-sulfamethoxazole .....	S	
Ceftazidime .....	R	
Ertapenem .....	R	carbapenems
Meropenem .....	R	
Aztreonam .....	S	
Colistin .....	I	
Doxycycline .....	S	
	(1)	

S = Susceptible I = Intermediate R = Resistant

## COMMENTS

A copy of this report has been generated for Infection Control.

# AMR-GNB:

## Antimicrobial resistant Gram-negative bacilli

---

### 1. >1 x 10E8/L of *Klebsiella pneumoniae/variicola*

Cephalexin is only indicated for the treatment of uncomplicated urinary tract infection. Nitrofurantoin is only indicated for the treatment of uncomplicated urinary tract infection. This isolate contains an extended spectrum beta lactamase (ESBL). This isolate should be considered clinically resistant to penicillins and aztreonam; susceptibility to specific cephalosporins and beta-lactam/inhibitor combinations should be based upon their in vitro susceptibility testing results. Consultation with the Infectious Disease Service is recommended.

### 2. >1 x 10E8/L of *Escherichia coli*

Nitrofurantoin is only indicated for the treatment of uncomplicated urinary tract infection. Cephalexin is only indicated for the treatment of uncomplicated urinary tract infection.

	1	2
Ampicillin .....	R	I
Amoxicillin-clavulanate	R	S
Piperacillin-tazobactam	 R	S
Cefazolin .....	R	S
Ceftriaxone.....	 R	
Ertapenem .....	S	
Meropenem .....	S	
Gentamicin .....	S	S
Ciprofloxacin .....	 R	R
Nitrofurantoin .....	I	S
Trimethoprim-sulfamethoxazole	 R	S
Cephalexin .....	R	S
Tobramycin .....	 R	S
Ceftazidime .....	R	

# *C. difficile*

---

Anaerobic Gram-positive bacilli, spore-former, GDH+, fluoresces under UV, “horse stable” smell

## Toxigenic *C. difficile*

- Toxin A and/or toxin B
- Disease spectrum: asymptomatic colonization – mild, self-limiting diarrhea – pseudomembranous colitis - toxic megacolon – sepsis – death
- Can cause outbreaks in health care facilities

```
===== STOOL FOR C. DIFFICILE TOXIN =====  
  
CRITICAL RESULT PHONED/FAXED at 13:45 on 24 Nov 22 to [REDACTED] by L6MB  
:pos C.diff result read back  
C. difficile toxin      Positive  
  
This test was performed using a Health Canada cleared nucleic acid  
amplification assay for the detection of a segment of C. difficile  
DNA known to be present in all known toxigenic strains of C. difficile,  
including A-B+ toxinotypes.  
  
COMMENTS  
A copy of this report has been generated for Infection Control.  
A copy of this report has been generated for Communicable Diseases.  
Illum ToxA/B wlu 1
```

